10-Q 1 vrnof-20220930.htm 10-Q vrnof-20220930
December 312022Q30001848416falseP6M00018484162022-01-012022-09-300001848416us-gaap:CommonClassAMember2022-11-11xbrli:shares0001848416us-gaap:CommonClassBMember2022-11-1100018484162022-09-30iso4217:USD00018484162021-12-3100018484162022-07-012022-09-3000018484162021-07-012021-09-3000018484162021-01-012021-09-300001848416us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-07-012022-09-300001848416us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-07-012021-09-300001848416us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-09-300001848416us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-01-012021-09-30iso4217:USDxbrli:shares0001848416us-gaap:CommonStockMember2021-06-300001848416us-gaap:AdditionalPaidInCapitalMember2021-06-300001848416us-gaap:RetainedEarningsMember2021-06-300001848416us-gaap:NoncontrollingInterestMember2021-06-3000018484162021-06-300001848416us-gaap:CommonStockMember2021-07-012021-09-300001848416us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001848416us-gaap:RetainedEarningsMember2021-07-012021-09-300001848416us-gaap:NoncontrollingInterestMember2021-07-012021-09-300001848416us-gaap:CommonStockMember2021-09-300001848416us-gaap:AdditionalPaidInCapitalMember2021-09-300001848416us-gaap:RetainedEarningsMember2021-09-300001848416us-gaap:NoncontrollingInterestMember2021-09-3000018484162021-09-3000018484162020-12-310001848416us-gaap:AdditionalPaidInCapitalMember2020-12-310001848416us-gaap:RetainedEarningsMember2020-12-310001848416us-gaap:NoncontrollingInterestMember2020-12-310001848416us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001848416us-gaap:CommonStockMember2021-01-012021-09-300001848416us-gaap:RetainedEarningsMember2021-01-012021-09-300001848416us-gaap:NoncontrollingInterestMember2021-01-012021-09-300001848416us-gaap:CommonStockMember2022-06-300001848416us-gaap:AdditionalPaidInCapitalMember2022-06-300001848416us-gaap:RetainedEarningsMember2022-06-300001848416us-gaap:NoncontrollingInterestMember2022-06-3000018484162022-06-300001848416us-gaap:CommonStockMember2022-07-012022-09-300001848416us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001848416us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001848416us-gaap:RetainedEarningsMember2022-07-012022-09-300001848416us-gaap:CommonStockMember2022-09-300001848416us-gaap:AdditionalPaidInCapitalMember2022-09-300001848416us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001848416us-gaap:RetainedEarningsMember2022-09-300001848416us-gaap:NoncontrollingInterestMember2022-09-300001848416us-gaap:CommonStockMember2021-12-310001848416us-gaap:AdditionalPaidInCapitalMember2021-12-310001848416us-gaap:RetainedEarningsMember2021-12-310001848416us-gaap:NoncontrollingInterestMember2021-12-310001848416us-gaap:CommonStockMember2022-01-012022-09-300001848416us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001848416us-gaap:NoncontrollingInterestMember2022-01-012022-09-300001848416us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001848416us-gaap:RetainedEarningsMember2022-01-012022-09-30vrnof:state0001848416srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2021-12-310001848416srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-03-310001848416srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-01-012022-03-310001848416srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2021-01-012021-03-310001848416srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2021-03-310001848416srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-01-012021-12-310001848416srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-03-31xbrli:pure00018484162020-12-1400018484162021-01-212021-01-2100018484162021-01-210001848416us-gaap:CommonClassAMember2021-02-112021-02-110001848416us-gaap:CommonClassBMember2021-02-112021-02-110001848416vrnof:AMEPartiesMemberus-gaap:CommonClassAMember2021-02-112021-02-110001848416vrnof:AMEPartiesMemberus-gaap:CommonClassBMember2021-02-112021-02-110001848416vrnof:AMEPartiesMember2021-02-112021-02-110001848416vrnof:AMEPartiesMember2021-02-1100018484162021-02-112021-02-110001848416us-gaap:LandMember2022-09-300001848416us-gaap:LandMember2021-12-310001848416us-gaap:BuildingAndBuildingImprovementsMember2022-09-300001848416us-gaap:BuildingAndBuildingImprovementsMember2021-12-310001848416us-gaap:FurnitureAndFixturesMember2022-09-300001848416us-gaap:FurnitureAndFixturesMember2021-12-310001848416vrnof:ComputerEquipmentAndSoftwareMember2022-09-300001848416vrnof:ComputerEquipmentAndSoftwareMember2021-12-310001848416us-gaap:LeaseholdImprovementsMember2022-09-300001848416us-gaap:LeaseholdImprovementsMember2021-12-310001848416us-gaap:MachineryAndEquipmentMember2022-09-300001848416us-gaap:MachineryAndEquipmentMember2021-12-310001848416us-gaap:VehiclesMember2022-09-300001848416us-gaap:VehiclesMember2021-12-310001848416us-gaap:AssetUnderConstructionMember2022-09-300001848416us-gaap:AssetUnderConstructionMember2021-12-310001848416us-gaap:CostOfSalesMember2022-07-012022-09-300001848416us-gaap:CostOfSalesMember2021-07-012021-09-300001848416us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001848416us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300001848416us-gaap:CostOfSalesMember2022-01-012022-09-300001848416us-gaap:CostOfSalesMember2021-01-012021-09-300001848416us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001848416us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300001848416us-gaap:LicensingAgreementsMember2021-12-310001848416us-gaap:TradeNamesMember2021-12-310001848416us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310001848416us-gaap:LicensingAgreementsMember2022-01-012022-09-300001848416us-gaap:TradeNamesMember2022-01-012022-09-300001848416us-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-09-300001848416us-gaap:LicensingAgreementsMember2022-09-300001848416us-gaap:TradeNamesMember2022-09-300001848416us-gaap:TechnologyBasedIntangibleAssetsMember2022-09-300001848416vrnof:CultivationSegmentMember2021-12-310001848416vrnof:CultivationSegmentMember2022-01-012022-09-300001848416vrnof:CultivationSegmentMember2022-09-300001848416vrnof:RetailSegmentMember2021-12-310001848416vrnof:RetailSegmentMember2022-01-012022-09-300001848416vrnof:RetailSegmentMember2022-09-300001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMember2022-01-012022-03-310001848416vrnof:CaringNatureLLCMember2022-07-012022-09-300001848416vrnof:A420CapitalManagementLLCMember2022-07-012022-09-3000018484162021-01-012021-01-2100018484162021-01-222021-09-300001848416us-gaap:NotesReceivableMember2021-12-31vrnof:receivable0001848416us-gaap:NotesReceivableMember2020-08-1300018484162020-08-130001848416us-gaap:NotesReceivableMember2020-08-132021-12-310001848416us-gaap:NotesReceivableMember2021-03-2400018484162021-03-240001848416us-gaap:NotesReceivableMember2022-09-300001848416vrnof:AMEPartiesMember2021-01-210001848416vrnof:AMEPartiesMember2021-08-112021-08-110001848416vrnof:AMEPartiesMember2022-01-012022-03-310001848416vrnof:AltMedFloridaMember2021-02-110001848416vrnof:AltMedArizonaMember2021-02-110001848416vrnof:AMEGroupMember2021-02-110001848416vrnof:AltMedFloridaMemberus-gaap:LicensingAgreementsMember2021-02-110001848416vrnof:AltMedArizonaMemberus-gaap:LicensingAgreementsMember2021-02-110001848416vrnof:AMEGroupMemberus-gaap:LicensingAgreementsMember2021-02-110001848416vrnof:AltMedFloridaMemberus-gaap:TradeNamesMember2021-02-110001848416vrnof:AltMedArizonaMemberus-gaap:TradeNamesMember2021-02-110001848416us-gaap:TradeNamesMembervrnof:AMEGroupMember2021-02-110001848416vrnof:AltMedFloridaMembervrnof:IntellectualPropertyAndTechnologyMember2021-02-110001848416vrnof:AltMedArizonaMembervrnof:IntellectualPropertyAndTechnologyMember2021-02-110001848416vrnof:IntellectualPropertyAndTechnologyMembervrnof:AMEGroupMember2021-02-110001848416vrnof:AltMedFloridaMembervrnof:ResidualPurchasePriceMember2021-02-110001848416vrnof:AltMedArizonaMembervrnof:ResidualPurchasePriceMember2021-02-110001848416vrnof:ResidualPurchasePriceMembervrnof:AMEGroupMember2021-02-110001848416vrnof:AltMedFloridaMembervrnof:DeferredTaxesMember2021-02-110001848416vrnof:AltMedArizonaMembervrnof:DeferredTaxesMember2021-02-110001848416vrnof:DeferredTaxesMembervrnof:AMEGroupMember2021-02-110001848416vrnof:AMEPartiesMember2021-01-012021-09-300001848416vrnof:GreengateMember2022-03-110001848416vrnof:GreengateMember2022-03-112022-03-110001848416vrnof:GreengateMember2022-01-012022-09-300001848416vrnof:SierraWellMember2022-09-070001848416vrnof:SierraWellMember2022-09-072022-09-070001848416vrnof:IssuedUponDeliveryOfLetterOfTransmittalMembervrnof:SierraWellMember2022-09-070001848416vrnof:SierraWellMembervrnof:IssuedAtClosingMember2022-09-072022-09-070001848416vrnof:IssuedUponDeliveryOfLetterOfTransmittalMembervrnof:SierraWellMember2022-09-072022-09-070001848416vrnof:HeldBackToSecureIndemnityClaimsMembervrnof:SierraWellMember2022-09-072022-09-070001848416vrnof:SierraWellMember2022-09-300001848416vrnof:ResidualPurchasePriceMembervrnof:SierraWellMember2022-09-070001848416vrnof:DeferredTaxesMembervrnof:SierraWellMember2022-09-070001848416vrnof:SierraWellMember2022-01-012022-09-300001848416vrnof:GreengateAndSierraWellMember2022-01-012022-09-300001848416vrnof:GlassCityAlternativesLLCMember2021-01-072021-01-070001848416vrnof:GlassCityAlternativesLLCMember2021-01-082022-01-070001848416vrnof:GlassCityAlternativesLLCMemberus-gaap:CommonClassAMember2021-01-072021-01-070001848416vrnof:GlassCityAlternativesLLCMember2021-01-070001848416vrnof:EmeraldMember2021-03-102021-03-100001848416vrnof:EmeraldMember2021-03-112022-03-100001848416vrnof:EmeraldMemberus-gaap:CommonClassAMember2021-03-102021-03-100001848416vrnof:EmeraldMemberus-gaap:CommonClassAMember2021-05-012021-05-310001848416vrnof:EmeraldMember2021-05-012021-05-310001848416vrnof:EmeraldMember2021-03-100001848416vrnof:EmeraldMembervrnof:ResidualPurchasePriceMember2021-03-100001848416vrnof:EmeraldMembervrnof:DeferredTaxesMember2021-03-100001848416vrnof:TheHerbalCareCenterMember2021-05-112021-05-11vrnof:license0001848416vrnof:TheHerbalCareCenterMember2021-05-122022-05-110001848416vrnof:TheHerbalCareCenterMember2021-02-242021-02-240001848416vrnof:TheHerbalCareCenterMemberus-gaap:CommonClassAMember2021-05-112021-05-110001848416us-gaap:CommonClassBMembervrnof:TheHerbalCareCenterMember2021-05-112021-05-110001848416vrnof:TheHerbalCareCenterMember2021-05-110001848416vrnof:ResidualPurchasePriceMembervrnof:TheHerbalCareCenterMember2021-05-110001848416vrnof:DeferredTaxesMembervrnof:TheHerbalCareCenterMember2021-05-110001848416vrnof:LocalJointMember2021-03-302021-03-300001848416vrnof:LocalJointMember2021-07-012021-07-310001848416vrnof:LocalJointMemberus-gaap:CommonClassAMember2021-03-302021-03-300001848416vrnof:LocalJointMember2021-03-300001848416vrnof:BISHCOLLCMember2021-02-232021-02-23vrnof:entity0001848416vrnof:BISHCOLLCMember2021-04-082021-04-080001848416vrnof:BISHCOLLCMember2021-04-092022-04-080001848416vrnof:BISHCOLLCMemberus-gaap:CommonClassAMember2021-04-082021-04-080001848416vrnof:BISHCOLLCMemberus-gaap:CommonClassBMember2021-04-082021-04-080001848416vrnof:BISHCOLLCMember2022-04-012022-04-300001848416vrnof:BISHCOLLCMember2022-09-300001848416vrnof:BISHCOLLCMember2021-04-080001848416vrnof:BISHCOLLCMembervrnof:ResidualPurchasePriceMember2021-04-080001848416vrnof:DeferredTaxesMembervrnof:BISHCOLLCMember2021-04-080001848416vrnof:TerraVidaHolisticCentersLLCMember2021-05-112021-05-11vrnof:dispensary0001848416vrnof:TerraVidaHolisticCentersLLCMember2021-05-122022-05-110001848416vrnof:TerraVidaHolisticCentersLLCMember2021-05-122021-11-110001848416vrnof:TerraVidaHolisticCentersLLCMemberus-gaap:CommonClassAMember2021-05-112021-05-110001848416us-gaap:CommonClassBMembervrnof:TerraVidaHolisticCentersLLCMember2021-05-112021-05-110001848416vrnof:TerraVidaHolisticCentersLLCMember2021-05-110001848416vrnof:TheHealingCenterMember2021-05-142021-05-140001848416vrnof:THCRealEstateMember2021-09-032021-09-030001848416vrnof:TheHealingCenterMember2021-05-152022-05-140001848416vrnof:TheHealingCenterMember2021-07-132021-07-130001848416vrnof:TheHealingCenterMemberus-gaap:CommonClassAMember2021-05-142021-05-140001848416vrnof:TheHealingCenterMemberus-gaap:CommonClassBMember2021-05-142021-05-140001848416vrnof:TheHealingCenterMember2021-05-140001848416vrnof:TheHealingCenterMember2021-05-152021-12-310001848416vrnof:TheHealingCenterMember2022-07-012022-09-300001848416vrnof:TheHealingCenterMember2022-01-012022-09-300001848416vrnof:TheHealingCenterMember2022-01-012022-03-310001848416vrnof:TheHealingCenterMemberus-gaap:CommonClassAMember2022-07-012022-09-300001848416vrnof:THCRealEstateMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2021-09-032021-09-030001848416vrnof:THCRealEstateMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2021-09-030001848416vrnof:MadRiverRemediesLLCMember2021-07-082021-07-080001848416vrnof:MadRiverRemediesLLCMember2021-07-092022-07-080001848416vrnof:MadRiverRemediesLLCMemberus-gaap:CommonClassAMember2021-07-082021-07-080001848416vrnof:MadRiverRemediesLLCMember2021-07-080001848416vrnof:AgriKindAndAgronomedHoldingsIncMember2021-07-122021-07-120001848416vrnof:AgriKindAndAgronomedHoldingsIncMember2021-07-132022-07-120001848416vrnof:AgriKindAndAgronomedHoldingsIncMember2021-07-132021-10-120001848416vrnof:AgriKindAndAgronomedHoldingsIncMemberus-gaap:CommonClassAMember2021-07-122021-07-120001848416vrnof:AgriKindAndAgronomedHoldingsIncMember2021-07-120001848416vrnof:AgriKindAndAgronomedHoldingsIncMember2022-01-012022-03-310001848416vrnof:AgriKindAndAgronomedHoldingsIncMember2022-07-012022-09-300001848416vrnof:AgriKindAndAgronomedHoldingsIncMember2022-04-010001848416vrnof:AgriKindAndAgronomedHoldingsIncMemberus-gaap:CommonClassAMember2022-01-012022-03-310001848416vrnof:AgriKindAndAgronomedHoldingsIncMemberus-gaap:CommonClassAMember2022-07-012022-09-300001848416vrnof:AgriKindAndAgronomedHoldingsIncMember2022-01-012022-09-300001848416vrnof:AgronomedMember2021-07-122021-07-120001848416vrnof:AgronomedMemberus-gaap:CommonClassAMember2021-07-122021-07-120001848416vrnof:AgronomedMember2021-07-120001848416vrnof:AgronomedMember2022-07-012022-09-300001848416vrnof:AgronomedMember2022-04-010001848416vrnof:AgronomedMember2022-01-012022-03-310001848416vrnof:AgronomedMemberus-gaap:CommonClassAMember2022-01-012022-03-310001848416vrnof:AgronomedMemberus-gaap:CommonClassAMembervrnof:EarnoutContingentConsiderationMember2022-01-012022-03-310001848416vrnof:AgronomedMembervrnof:EarnoutContingentConsiderationMember2022-01-012022-03-310001848416vrnof:AgronomedMemberus-gaap:CommonClassAMember2022-07-012022-09-300001848416vrnof:AgronomedMember2022-01-012022-09-300001848416vrnof:AgronomedMembervrnof:EarnoutContingentConsiderationMember2022-09-300001848416vrnof:ResidualPurchasePriceMembervrnof:AgronomedMember2021-07-120001848416vrnof:DeferredTaxesMembervrnof:AgronomedMember2021-07-120001848416vrnof:WillowBrookWellnessLLCMember2021-10-252021-10-250001848416vrnof:WillowBrookWellnessLLCMemberus-gaap:SubsequentEventMember2021-10-262022-10-250001848416vrnof:WillowBrookWellnessLLCMemberus-gaap:CommonClassAMember2021-10-252021-10-250001848416vrnof:WillowBrookWellnessLLCMember2022-09-300001848416vrnof:WillowBrookWellnessLLCMember2021-10-250001848416vrnof:CaringNatureLLCMember2021-12-202021-12-200001848416vrnof:CaringNatureLLCMember2022-05-012022-05-310001848416vrnof:CaringNatureLLCMember2022-04-012022-06-300001848416vrnof:CaringNatureLLCMember2021-12-200001848416vrnof:CaringNatureLLCMemberus-gaap:CommonClassAMember2022-04-012022-06-300001848416vrnof:CaringNatureLLCMemberus-gaap:CommonClassAMember2022-07-012022-09-300001848416vrnof:CaringNatureLLCMember2022-01-012022-09-300001848416vrnof:CaringNatureLLCMember2022-09-300001848416vrnof:CaringNatureLLCMembervrnof:ResidualPurchasePriceMember2021-12-200001848416vrnof:DeferredTaxesMembervrnof:CaringNatureLLCMember2021-12-200001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMember2021-12-282021-12-280001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMemberus-gaap:CommonClassAMember2021-12-282021-12-280001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMembersrt:ScenarioForecastMemberus-gaap:CommonClassAMember2022-12-012022-12-310001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMember2022-09-300001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMemberus-gaap:CommonClassAMember2022-09-300001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMemberus-gaap:CommonClassAMember2022-06-012022-06-300001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMember2022-06-012022-06-300001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMember2022-01-012022-09-300001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMemberus-gaap:LicensingAgreementsMember2021-12-280001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMemberus-gaap:TradeNamesMember2021-12-280001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMembervrnof:ResidualPurchasePriceMember2021-12-280001848416vrnof:ConnecticutPharmaceuticalSolutionsIncMembervrnof:DeferredTaxesMember2021-12-280001848416us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-09-300001848416vrnof:AMEPartiesMember2021-07-012021-09-300001848416us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-07-012021-09-300001848416srt:ParentCompanyMember2021-01-012021-09-300001848416srt:ParentCompanyMembervrnof:IntangibleAmortizationAdjustmentMember2021-01-012021-09-300001848416vrnof:AMEPartiesMembervrnof:IntangibleAmortizationAdjustmentMember2021-01-012021-09-300001848416us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembervrnof:IntangibleAmortizationAdjustmentMember2021-01-012021-09-300001848416vrnof:IntangibleAmortizationAdjustmentMember2021-01-012021-09-300001848416vrnof:InventoryStepUpAdjustmentMembersrt:ParentCompanyMember2021-01-012021-09-300001848416vrnof:InventoryStepUpAdjustmentMembervrnof:AMEPartiesMember2021-01-012021-09-300001848416vrnof:InventoryStepUpAdjustmentMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-09-300001848416vrnof:InventoryStepUpAdjustmentMember2021-01-012021-09-300001848416vrnof:IntangibleAmortizationAndInventoryStepUpAdjustmentMembersrt:ParentCompanyMember2021-01-012021-09-300001848416vrnof:AMEPartiesMembervrnof:IntangibleAmortizationAndInventoryStepUpAdjustmentMember2021-01-012021-09-300001848416us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembervrnof:IntangibleAmortizationAndInventoryStepUpAdjustmentMember2021-01-012021-09-300001848416vrnof:IntangibleAmortizationAndInventoryStepUpAdjustmentMember2021-01-012021-09-300001848416srt:ParentCompanyMember2021-07-012021-09-300001848416srt:ParentCompanyMembervrnof:IntangibleAmortizationAdjustmentMember2021-07-012021-09-300001848416vrnof:AMEPartiesMembervrnof:IntangibleAmortizationAdjustmentMember2021-07-012021-09-300001848416us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembervrnof:IntangibleAmortizationAdjustmentMember2021-07-012021-09-300001848416vrnof:IntangibleAmortizationAdjustmentMember2021-07-012021-09-300001848416vrnof:InventoryStepUpAdjustmentMembersrt:ParentCompanyMember2021-07-012021-09-300001848416vrnof:InventoryStepUpAdjustmentMembervrnof:AMEPartiesMember2021-07-012021-09-300001848416vrnof:InventoryStepUpAdjustmentMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-07-012021-09-300001848416vrnof:InventoryStepUpAdjustmentMember2021-07-012021-09-300001848416vrnof:IntangibleAmortizationAndInventoryStepUpAdjustmentMembersrt:ParentCompanyMember2021-07-012021-09-300001848416vrnof:AMEPartiesMembervrnof:IntangibleAmortizationAndInventoryStepUpAdjustmentMember2021-07-012021-09-300001848416us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMembervrnof:IntangibleAmortizationAndInventoryStepUpAdjustmentMember2021-07-012021-09-300001848416vrnof:IntangibleAmortizationAndInventoryStepUpAdjustmentMember2021-07-012021-09-300001848416vrnof:NSEMember2021-03-092021-03-090001848416vrnof:NSEMemberus-gaap:CommonClassAMember2021-03-092021-03-090001848416us-gaap:CommonClassBMembervrnof:NSEMember2021-03-092021-03-090001848416vrnof:NSEMember2021-03-102021-12-310001848416vrnof:NSEMember2022-01-012022-09-300001848416vrnof:NSEMember2022-09-300001848416vrnof:OhioGrownTherapiesLLCMember2021-06-302021-06-300001848416vrnof:MarylandLLCMembervrnof:CannaCuzzosMember2018-12-310001848416vrnof:CannaCuzzosMember2018-12-310001848416vrnof:CannaCuzzosMember2022-01-312022-01-310001848416vrnof:CannaCuzzosMember2022-01-012022-09-300001848416vrnof:ILDISPLLCMember2016-03-300001848416vrnof:ILDISPLLCMember2016-03-302016-03-300001848416vrnof:ILDISPLLCMember2022-03-010001848416vrnof:ILDISPLLCMember2022-03-012022-03-010001848416vrnof:ILDISPLLCCharlestonDispensaryMember2022-03-012022-03-010001848416vrnof:ILDISPLLCTCEDispensaryMember2022-03-012022-03-010001848416vrnof:ILDISPLLCMember2022-04-012022-06-300001848416vrnof:ILDISPLLCCharlestonDispensaryMember2022-04-012022-06-300001848416vrnof:ILDISPLLCTCEDispensaryMember2022-04-012022-06-300001848416vrnof:ILDISPLLCMember2022-07-012022-09-300001848416vrnof:ILDISPLLCCharlestonDispensaryMember2022-07-012022-09-300001848416vrnof:ILDISPLLCTCEDispensaryMember2022-07-012022-09-300001848416vrnof:ILDISPLLCCharlestonDispensaryMember2022-01-012022-09-300001848416vrnof:ILDISPLLCTCEDispensaryMember2022-01-012022-09-300001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-09-300001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2021-12-310001848416us-gaap:NotesPayableOtherPayablesMember2022-09-300001848416us-gaap:NotesPayableOtherPayablesMember2021-12-310001848416us-gaap:MortgagesMember2022-09-300001848416us-gaap:MortgagesMember2021-12-310001848416vrnof:VehicleAndEquipmentLoansMember2022-09-300001848416vrnof:VehicleAndEquipmentLoansMember2021-12-310001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembervrnof:CreditFacilityMember2020-07-020001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembervrnof:CreditFacilityMember2021-05-100001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembervrnof:CreditFacilityMember2021-05-090001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembervrnof:CreditFacilityMember2021-10-200001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembervrnof:CreditFacilityMember2022-03-010001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembervrnof:CreditFacilityMember2022-09-300001848416us-gaap:MortgagesMember2022-06-290001848416vrnof:AgriKindAndAgronomedHoldingsIncMember2021-07-11vrnof:instrument0001848416srt:AffiliatedEntityMemberus-gaap:NotesPayableOtherPayablesMember2021-12-310001848416us-gaap:CommonClassAMember2022-09-300001848416us-gaap:CommonClassBMember2022-09-30vrnof:class0001848416us-gaap:CommonClassAMember2022-01-012022-09-30vrnof:vote0001848416us-gaap:CommonClassBMember2022-01-012022-09-300001848416us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-09-300001848416srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001848416srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001848416srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001848416us-gaap:EmployeeStockOptionMember2022-01-012022-09-30iso4217:CADxbrli:shares00018484162021-01-012021-12-310001848416us-gaap:RestrictedStockUnitsRSUMember2021-12-310001848416us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001848416us-gaap:RestrictedStockUnitsRSUMember2022-09-300001848416us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001848416us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001848416us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001848416us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001848416us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300001848416us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-30vrnof:segment0001848416vrnof:CultivationSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001848416vrnof:CultivationSegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001848416vrnof:CultivationSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001848416vrnof:CultivationSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300001848416us-gaap:OperatingSegmentsMembervrnof:RetailSegmentMember2022-07-012022-09-300001848416us-gaap:OperatingSegmentsMembervrnof:RetailSegmentMember2021-07-012021-09-300001848416us-gaap:OperatingSegmentsMembervrnof:RetailSegmentMember2022-01-012022-09-300001848416us-gaap:OperatingSegmentsMembervrnof:RetailSegmentMember2021-01-012021-09-300001848416us-gaap:IntersegmentEliminationMember2022-07-012022-09-300001848416us-gaap:IntersegmentEliminationMember2021-07-012021-09-300001848416us-gaap:IntersegmentEliminationMember2022-01-012022-09-300001848416us-gaap:IntersegmentEliminationMember2021-01-012021-09-300001848416vrnof:CultivationSegmentMember2022-07-012022-09-300001848416vrnof:CultivationSegmentMember2021-07-012021-09-300001848416vrnof:CultivationSegmentMember2021-01-012021-09-300001848416vrnof:RetailSegmentMember2022-07-012022-09-300001848416vrnof:RetailSegmentMember2021-07-012021-09-300001848416vrnof:RetailSegmentMember2021-01-012021-09-30vrnof:reportingUnit0001848416srt:MinimumMember2021-12-310001848416srt:MaximumMember2021-12-31vrnof:loyaltyPoint0001848416srt:MinimumMember2022-09-300001848416srt:MaximumMember2022-09-300001848416us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-09-300001848416srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember2022-09-300001848416us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-12-310001848416srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember2021-12-310001848416us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001848416us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001848416us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300001848416us-gaap:FairValueMeasurementsRecurringMember2022-09-300001848416us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001848416us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001848416us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001848416us-gaap:FairValueMeasurementsRecurringMember2021-12-310001848416vrnof:GoodnessGrowthHoldingsMemberus-gaap:SubsequentEventMember2022-10-130001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMembervrnof:CreditAgreement2022Member2022-10-270001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMembervrnof:CreditAgreement2022Member2022-10-272022-10-270001848416us-gaap:PrimeRateMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMembervrnof:CreditAgreement2022Member2022-10-272022-10-270001848416us-gaap:PrimeRateMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembersrt:MinimumMemberus-gaap:SubsequentEventMembervrnof:CreditAgreement2022Member2022-10-272022-10-270001848416us-gaap:PrimeRateMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembersrt:MaximumMemberus-gaap:SubsequentEventMembervrnof:CreditAgreement2022Member2022-10-272022-10-270001848416us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembersrt:ChiefExecutiveOfficerMemberus-gaap:SubsequentEventMembervrnof:CreditAgreement2022Member2022-10-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 000-56342
VERANO HOLDINGS CORP.
(Exact name of registrant as specified in its charter)
British Columbia, Canada98-1583243
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
415 North Dearborn Street, 4th Floor, Chicago, Illinois
60654
(Address of Principal Executive Offices)
(Zip Code)

Registrant's telephone number, including area code: (312) 265 0730
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
N/AN/AN/A
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes o No x
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
o
Accelerated filer
o
Non-accelerated filer
x
Smaller reporting company
o
Emerging growth company
x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
The registrant had outstanding 324,317,749 Class A Subordinate Voting Shares and 133,823 Class B Proportionate Voting Shares for a total of 337,700,057 Class A Subordinate Voting Shares on an as converted basis as of November 11, 2022.


TABLE OF CONTENTS
Pages


PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
VERANO HOLDINGS CORP.
Condensed Consolidated Balance Sheets
($ in Thousands)
September 30,
2022
December 31,
2021
(Unaudited)(As Restated)
ASSETS
Current Assets:
Cash and Cash Equivalents$76,418 $99,118 
Accounts Receivable, net15,201 17,410 
Notes Receivable 285 
Inventory168,142 140,703 
Prepaid Expenses and Other Current Assets35,309 19,528 
Total Current Assets295,070 277,044 
Property, Plant and Equipment, net533,753 452,232 
Right of Use Assets, net77,507 61,346 
Intangible Assets, net1,326,601 1,379,913 
Goodwill380,408 368,130 
Investment in Associates7,043 7,491 
Deposits and Other Assets2,645 2,499 
TOTAL ASSETS$2,623,027 $2,548,655 
LIABILITIES AND SHAREHOLDERS’ EQUITY
LIABILITIES
Current Liabilities:
Accounts Payable$52,205 $45,172 
Accrued Liabilities32,054 42,149 
Income Tax Payable222,323 154,512 
Current Portion of Lease Liabilities8,532 6,563 
Current Portion of Notes Payable15,344 13,771 
Acquisition Consideration Payable53,739 208,349 
Total Current Liabilities384,197 470,516 
Long-Term Liabilities:
Deferred Revenue215 1,183 
Notes Payable, net of Current Portion376,791 276,154 
Lease Liabilities, net of Current Portion71,811 56,812 
Deferred Income Taxes249,719 262,184 
Total Long-Term Liabilities698,536 596,333 
TOTAL LIABILITIES$1,082,733 $1,066,849 
SHAREHOLDERS’ EQUITY1,540,294 1,480,530 
NON-CONTROLLING INTEREST 1,276 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$2,623,027 $2,548,655 
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
1

VERANO HOLDINGS CORP.
Unaudited Interim Condensed Consolidated Statements of Operations
($ in Thousands except share and per share amounts)
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Revenues, net of Discounts$227,588 $206,469 $653,485 $526,430 
Cost of Goods Sold, net104,594 108,268 333,759 304,729 
Gross Profit122,994 98,201 319,726 221,701 
Selling, General, and Administrative Expenses85,710 76,477 275,531 189,155 
Income (Loss) from Investments in Associates(209)1,289 1,651 2,737 
Income from Operations37,075 23,013 45,846 35,283 
Other Income (Expense):
Gain (loss) on Disposal of Property, Plant and Equipment1,443 (9)251 (438)
Gain on Deconsolidation75  9,560  
Gain on Previously Held Equity Interest175  14,103  
Interest Expense, net(11,785)(8,113)(34,082)(15,314)
Other Income (Expense), net(595)233 17,557 (764)
Total Other Income (Expense)(10,687)(7,889)7,389 (16,516)
Net Income Before Provision for Income Taxes and
Non-Controlling Interest
26,388 15,124 53,235 18,767 
Provision For Income Taxes(69,381)(27,086)(105,998)(66,939)
Net Loss Before Non-Controlling Interest(42,993)(11,962)(52,763)(48,172)
Net Income Attributable to Non-Controlling Interest 551 291 1,915 
Net Loss Attributable to Verano Holdings Corp.$(42,993)$(12,513)$(53,054)$(50,087)
Net Loss per share – basic$(0.13)$(0.04)$(0.16)$(0.18)
Net Loss per share – diluted$(0.13)$(0.04)$(0.16)$(0.18)
Basic – weighted average shares outstanding332,872,464 313,674,044 329,240,200 281,961,659 
Diluted – weighted average shares outstanding332,872,464 313,674,044 329,240,200 281,961,659 
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
2

VERANO HOLDINGS CORP.
Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity
($ in Thousands)
LLC
Membership
Units
SVS Shares
(as converted)
Share
Capital
Accumulated
Earnings (Deficit)
Non-Controlling
Interest
Total
Balance as of July 1, 2021— 307,223,181 $1,253,867 $(28,327)$7,501 $1,233,041 
Share-based compensation— 932,525 13,826 — — 13,826 
Issuance of shares in conjunction with acquisitions— 7,043,645 111,268 — — 111,268 
Purchase of Non-controlling interest— — 505 (6,975)(5,795)(12,265)
Distributions to minority holders— — — — (1,375)(1,375)
Net income (loss)— — — (12,513)551 (11,962)
Balance as of September 30, 2021— 315,199,351 $1,379,466 $(47,815)$882 $1,332,533 
Balance as of January 1, 2021279,900,000 — $137,914 $9,247 $6,237 $153,398 
RTO-related issuances, net— — 652,217 — — 652,217 
Issuance of Pubco shares in redemption of membership units(279,900,000)279,900,000 — — — — 
Reverse takeover (“RTO Financing”), net— 10,100,000 95,420 — — 95,420 
Purchase of Non-controlling interest— — 505 (6,975)(5,795)(12,265)
Distributions to minority holders— — — — (1,475)(1,475)
Share-based compensation— 932,525 34,923 — — 34,923 
Issuance of shares in conjunction with acquisitions— 20,653,051 381,302 — — 381,302 
Warrants issued and exercised— 3,510,000 75,100 — — 75,100 
Contingent consideration & other adjustments to purchase accounting— 103,775 2,085 — — 2,085 
Net income (loss)— — — (50,087)1,915 (48,172)
Balance as of September 30, 2021— 315,199,351 $1,379,466 $(47,815)$882 $1,332,533 

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
3

VERANO HOLDINGS CORP.
Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (Continued)
($ in Thousands)
LLC
Membership
Units
SVS Shares
(as converted)
Share
Capital
Accumulated Other Comprehensive IncomeAccumulated
Earnings (Deficit)
Non-Controlling
Interest
Total
Balance as of July 1, 2022— 330,818,664 $1,614,021 $— $(65,296)$ $1,548,725 
Share-based compensation— 1,815,430 12,399 — — — 12,399 
Issuance of shares in conjunction with acquisitions
— 1,714,358 12,356 — — — 12,356 
Foreign Currency Translation Adjustment— — — 103 — — 103 
Contingent consideration & other adjustments to purchase accounting— 1,813,770 9,704 — — — 9,704 
Net loss
— — — — (42,993)— (42,993)
Balance as of September 30, 2022— 336,162,222 $1,648,480 $103 $(108,289)$ $1,540,294 
Balance as of January 1, 2022
(As Restated)
— 324,312,662 $1,535,765 $— $(55,235)$1,276 $1,481,806 
Share-based compensation— 2,613,337 36,664 — — — 36,664 
Issuance of shares in conjunction with acquisitions— 3,925,683 31,116 — — — 31,116 
Non-controlling interest adjustment for change in ownership— — — — — (1,567)(1,567)
Foreign Currency Translation Adjustment— — — 103 — — 103 
Contingent consideration & other adjustments to purchase accounting— 5,310,540 44,935 — — — 44,935 
Net income (loss)— — — — (53,054)291 (52,763)
Balance as of September 30, 2022— 336,162,222 $1,648,480 $103 $(108,289)$ $1,540,294 
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
4

VERANO HOLDINGS CORP.
Unaudited Interim Condensed Consolidated Statements of Cash Flows
($ in Thousands)
Nine Months Ended September 30,
20222021
CASH FLOW FROM OPERATING ACTIVITIES
Net loss attributable to Verano Holdings Corp. and Subsidiaries$(53,054)$(50,087)
Net income attributable to non-controlling interest291 1,915 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization106,230 65,620 
Right of use assets amortization6,465 3,643 
Non-cash interest expense2,183 5,082 
Non-cash interest income (145)
Non-cash inventory step-up expense on acquisitions6,818 80,907 
(Gain) Loss on disposal of property, plant and equipment(251)438 
Gain on deconsolidation(9,560) 
Gain on investments in associates(14,103)(1,475)
Bad debt expense152 85 
Amortization of debt issuance costs5,039 1,248 
Unrealized gain on foreign currency translation(26) 
Unrealized loss on marketable securities1,781  
Income from underlying investees(101)(1,408)
Stock earnout for acquisitions 2,084 
Increase (decrease) in fair value of contingent consideration(13,925)1,212 
Stock based compensation34,225 31,722 
Changes in operating assets and liabilities:  
Accounts receivable2,056 (14,263)
Inventory(28,997)(49,175)
Prepaid expenses and other current assets(13,306)(1,546)
Deposits and other assets(299)(1,147)
Accounts payable6,152 (541)
Accrued liabilities(17,356)(8,851)
Lease liabilities(5,634)(2,514)
Income tax payable65,701 57,723 
Deferred taxes(14,199) 
Other, net(971)(662)
NET CASH PROVIDED BY OPERATING ACTIVITIES65,311 119,865 
CASH FLOW FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment(109,720)(91,952)
Proceeds from disposal of assets6,006 896 
Distributions to minority members (1,475)
Purchases of intangible assets (8,374)
Purchase of non-controlling interest (7,840)
Acquisition of business, net of cash acquired(101,396)(217,372)
Proceeds from sale of deconsolidation and investment in associates19,826  
Purchase of interest in investment in associates (3,350)
Dividend received from investments in associates 10,275 
Proceeds from note receivable 4,215 
Other, net 103 
NET CASH USED IN INVESTING ACTIVITIES(185,284)(314,874)
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
5

VERANO HOLDINGS CORP.
Unaudited Interim Condensed Consolidated Statements of Cash Flows (Continued)
($ in Thousands)
Nine Months Ended September 30,
20222021
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issuance of notes payable$122,057 $100,000 
Principal repayments of notes payable(21,901)(9,843)
Debt issuance costs paid(2,986)(5,132)
Proceeds received from RTO Financing, net 75,420 
Cash received from warrant private placement 75,100 
NET CASH PROVIDED BY FINANCING ACTIVITIES97,170 235,545 
Effects of exchange rate fluctuations on cash and cash equivalents103  
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS(22,700)40,536 
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD99,118 16,402 
CASH AND CASH EQUIVALENTS, END OF PERIOD$76,418 $56,938 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest paid, net$31,899 $10,378 
NONCASH INVESTING AND FINANCING ACTIVITIES
Accrued capital expenditures$5,875 $7,928 
Issuance of shares under business combinations$76,010 $1,007,322 
Acquisitions
Tangible and intangible assets acquired, net of cash$35,713 $1,428,910 
Liabilities assumed(10,616)(302,437)
Acquisition consideration payable64,021 (1,208,143)
Goodwill12,278 299,042 
$101,396 $217,372 
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
6

VERANO HOLDINGS CORP.
Notes to Unaudited Interim Condensed Consolidated Financial Statements
($ in Thousands except shares and per share amounts)
1.OVERVIEW AND BASIS OF PRESENTATION
(a)Description of Business
Unless otherwise stated or the context requires otherwise, references herein to the "Company,” “Verano,” "we," "us," and "our" are intended to mean Verano Holdings Corp. and its direct and indirect subsidiaries, licensees, and controlled and managed entities.
The Company is a vertically integrated cannabis operator that focuses on limited-licensed markets in the United States. As a vertically integrated provider, the Company owns, operates, manages, controls, and/or has licensing, consulting or other commercial agreements with cultivation, processing, and retail licensees across 14 state markets (Arizona, Arkansas, California, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, and West Virginia).
In addition to the states listed above, the Company also conducts pre-licensing activities in other markets. In these markets, the Company has either applied for licenses, or plans on applying for licenses, but does not currently own any cultivation, processing, or retail licenses.
On February 11, 2021, the Company resulted from a reverse takeover transaction as further described in Note 3. Thereafter, the Company’s Class A Subordinate Voting Shares (the “Subordinate Voting Shares”) were listed on the Canadian Securities Exchange (the “CSE”) under ticker symbol “VRNO” and subsequently began to be quoted in the United States on the OTCQX marketplace operated by the OTC Market Group, under the ticker symbol “VRNOF”.
The Company’s corporate headquarters is located at 415 North Dearborn St., 4th Floor, Chicago, Illinois 60654.
(b)Basis of Presentation
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Unless otherwise indicated, all references to “$” or “US$” in this document refer to United States dollars, and all references to “C$” refer to Canadian dollars. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's restated audited consolidated financial statements and notes thereto for as of and for the year ended December 31, 2021, included in the Company’s Amendment No. 2 to Form 10 filed with the SEC on August 19, 2022 (the "2021 Annual Audited Financials"), which amended the Company's registration statement on Form 10 initially filed with the SEC on April 26, 2022, as further amended on June 17, 2022 and September 8, 2022 (as amended through September 8, 2022, the "Form 10"). The accompanying unaudited interim condensed consolidated financial statements include the accounts of Verano Holdings, Corp. and its direct and indirect subsidiaries as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with Accounting Standards Codification ("ASC") 810 Consolidation. The preparation of the Company’s unaudited interim condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of assets and liabilities in such financial statements and in the accompanying notes. Actual results may differ materially from these estimates. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the 2022 full year or any future periods. The accompanying condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited consolidated balance sheet as of December 31, 2021 contained in the Form 10.

7

VERANO HOLDINGS CORP.
Notes to Unaudited Interim Condensed Consolidated Financial Statements
($ in Thousands except shares and per share amounts)
1.OVERVIEW AND BASIS OF PRESENTATION (Continued)

(c)Restatement of Previously Issued Consolidated Financial Statements

The notes included herein should be read in conjunction with the Company’s 2021 Annual Audited Consolidated Financial Statements. As described in the Form 10, the Company restated it's previously issued consolidated financial statements for each of the quarterly and year-to-date periods ended March 31, 2022, December 31, 2021, and March 31, 2021 (collectively, as the "Restatements"). Amounts as of or for the period ended December 31, 2021 depicted in these interim unaudited condensed consolidated financial statements as "As Restated" include the impact of the restatement included in the Form 10. As a result of the error related to stock-based compensation, the Company increased Inventories by $3,069 as of and for the year ended December 31, 2021. As a result of such understated stock-based compensation expense, the Company’s tax expense was overstated with corresponding adjustments to Income Tax Payable of $662 and a decrease of Deferred Income Taxes of ($800) as of and for the year ended December 31, 2021. As a result of the error related to stock-based compensation as of and for the quarter ended March 31, 2022, the Company increased Inventories by $3,898, Cost of Goods Sold, net by $1,052, and Salaries and Benefits expense by $9,572. As a result of the error related to stock-based compensation as of and for the quarter ended March 31, 2021, the Company increased Salaries and Benefits expense by $5,692. As a result of overstatement of tax expense due to a clerical error, the Company’s tax expense was overstated by $20,274 with corresponding adjustments to Income Tax Payable of ($23,071) and an increase to Deferred Income Taxes of $2,659 as of and for the quarter ended March 31, 2022. There was no net cash impact to the audited consolidated financial statements for the year ended December 31, 2021 and no net cash impact to the unaudited interim condensed consolidated financial statements for the quarters ended March 31, 2022 and 2021, for these restatement items. The Company’s accounting for distributions from a consolidated entity was corrected in the Restatements to reduce Investment in Associates and Non-controlling Interest Equity by ($1,675) for the year ended December 31, 2021, and ($100) for the quarter ended March 31, 2021. Also, the Investment in Associates was corrected to account for distributions in excess of investment resulting in an increase of Equity Income of $1,537 and $1,638 at, December 31, 2021 and March 31, 2022, respectively, with a reduction in Disposition of Investments of $3,176 at March 31, 2022. Additionally, The Company determined that it had information after March 31, 2022 but before the March 31, 2022 financials were publicly filed regarding the Connecticut Pharmaceutical Solutions, Inc. and The Healing Center, LLC acquisition earnouts, as described in Note 8 - Transactions, below. As a result, the Company recognized an aggregate $4,760 reduction in these expected acquisition earnouts which was recorded in the quarter ended March 31, 2022 to reflect the subsequent information indicating a lower liability. For additional information regarding the Restatements, please refer to the Form 10.
(d)Basis of Consolidation
The condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its subsidiaries, as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with ASC 810 Consolidation. All transactions and balances between these entities have been eliminated upon consolidation.
(d)Significant Accounting Policies
There have been no changes to the Company’s significant accounting policies as described in Note 2 to the 2021 Annual Audited Financials, included in the Form 10.
(e)Earnings (Loss) per Share
Basic earnings (loss) per share is calculated using the treasury stock method, by dividing the net earnings (losses) attributable to shareholders by the weighted average number of shares (including the Company's Class B Proportionate Voting Shares (the "Proportionate Voting Shares") on an as converted to Subordinate Voting Shares basis of 100 Subordinate Voting Shares to one Proportionate Voting Share) outstanding during each of the periods presented. Contingently issuable shares (including shares held in escrow) are not considered outstanding shares and
8

VERANO HOLDINGS CORP.
Notes to Unaudited Interim Condensed Consolidated Financial Statements
($ in Thousands except shares and per share amounts)
1.OVERVIEW AND BASIS OF PRESENTATION (Continued)
consequently are not included in the earnings (loss) per share calculations. Diluted income per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares.
To determine diluted income per share, the Company assumes that any proceeds from the exercise of dilutive share options would be used to repurchase shares at the average market price during the period. The diluted income per share calculation excludes any potential conversion of share options and convertible debt, if any, that would increase earnings per share or decrease loss per share. No potentially dilutive share equivalents were included in the computation of diluted loss per share for the three and nine months ended September 30, 2022 and 2021 because their impact would have been anti-dilutive.
(f)Recently Issued Accounting Standards
The Company reviews recently issued accounting standards on a quarterly basis and has determined there are no standards yet to be adopted which are relevant to the Company’s business for disclosure.
(g)Coronavirus Pandemic

In March 2020, the World Health Organization categorized coronavirus disease 2019 (together with its variants, “COVID-19”) as a pandemic. COVID-19 has spread throughout the U.S. and other countries across the world. Although the duration and severity of its effects are currently unknown, the Company continues to assess the potential impact on the Company and evaluate actions to strengthen its financial position and support the continuity of its business and operations in response to the effects of COVID-19.

While the Company believes that its revenue, gross profit and operating income were not adversely impacted by COVID-19 during the three and nine months ended September 30, 2022, the uncertain nature of the spread of variants of COVID-19 could alter the Company’s financial results and business operations, including as a result of any lockdowns mandated by governmental authorities and the potential quarantine of the Company’s employees or of its supply chain partners’ employees.

The Company’s unaudited interim condensed consolidated financial statements presented herein reflect estimates and assumptions made by management taking into account, among other matters, the impact of COVID-19. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of such financial statements and reported amounts of revenue and expenses during the periods presented. Such estimates and assumptions affect, among other things, the Company’s goodwill; long-lived assets and intangible assets; operating lease right of use assets and operating lease liabilities; valuation of deferred income taxes; the allowance for doubtful accounts; assessment of the Company’s lease and non-lease contract expenses; and measurement of compensation cost for bonus and other compensation plans.
2.REVERSE TAKEOVER TRANSACTION (“RTO”)
On December 14, 2020, Verano Holdings, LLC, a Delaware limited liability company and currently a subsidiary of the Company ("Verano LLC"), Majesta Minerals, Inc., an Alberta corporation (the “Public Corporation”), 1276268 B.C. Ltd., a British Columbia corporation (“Verano FinCo”), 1277233 B.C. Ltd, a British Columbia corporation, and 1278655 B.C. Ltd., a British Columbia corporation (“Majesta SubCo”), entered into an arrangement agreement (as amended January 26, 2021, the “Definitive Agreement”), pursuant to which the Company resulted from the reverse takeover transaction contemplated thereby (the “RTO”).
In accordance with the plan of arrangement forming part of the Definitive Agreement (the “Plan of Arrangement”), the Public Corporation changed its name to “Verano Holdings Corp.” and completed a consolidation of its common shares on the basis of 100,000 issued and outstanding common shares on a post-consolidation basis.
9

VERANO HOLDINGS CORP.
Notes to Unaudited Interim Condensed Consolidated Financial Statements
($ in Thousands except shares and per share amounts)
2.REVERSE TAKEOVER TRANSACTION (“RTO”) (Continued)
In accordance with the terms of the Plan of Arrangement, 10,000,000 subscription receipts (the “Subscription Receipts”) were issued on January 21, 2021, at a price per Subscription Receipt of $101, for aggregate gross proceeds of $100,000 (the “RTO Financing”). As part of the RTO Financing, the Company issued a total of 10,000,000 Subordinate Voting Shares to the purchasers of the Subscription Receipts, issued 578,354 Subordinate Voting Shares and paid $4,580 in transactions costs to the offering agents as a broker fee, for a net RTO Financing amount of $95,420.

The Public Corporation reorganized its capital structure by altering its notice of articles and articles to (i) attach special rights and restrictions to its common shares, (ii) change the identifying name of its common shares to “Class A Subordinate Voting Shares” and (iii) create a new class of shares identified as "Class B Proportionate Voting Shares". Pursuant to the Plan of Arrangement, thereafter Verano FinCo amalgamated with Majesta SubCo. Majesta SubCo subsequently was liquidated, and the net proceeds of the RTO Financing were transferred to the Company, as the resulting corporation in the RTO.
The members of Verano LLC, and owners of certain of its subsidiaries, through a series of transactions, exchanged their ownership interests in Verano LLC and such subsidiaries for 96,892,040 Subordinate Voting Shares and 1,172,382 Proportionate Voting Shares. In connection with the Company’s acquisitions of Alternative Medical Enterprises, LLC, Plants of Ruskin GPS, LLC, and RVC 360, LLC (collectively, the “AME Parties”), that occurred concurrently with the RTO, the members of the AME Parties, through a series of transactions, exchanged their membership interests in the AME Parties for 18,092,987 Subordinate Voting Shares and 470,984 Proportionate Voting Shares. In addition, upon the consummation of the acquisitions the members of the AME Parties received cash consideration of $20,000, which was funded with proceeds from the RTO Financing and were entitled to receive an additional $15,000 in future cash installments, all of which have been paid in full. Refer to Note 8 - Transactions, below for additional details of the acquisitions of the AME Parties and related transactions.
In accordance with ASC 805, Business Combinations, the substance of the RTO transactions is a reverse takeover of a nonoperating company. The RTO transactions do not constitute a business combination because Majesta SubCo does not meet the definition of a business under the standard. As a result, the RTO transactions are accounted for as a capital transaction with Verano LLC being identified as the acquirer and the equity consideration being measured at fair value. The resulting consolidated statement of financial position of the Company is presented as a continuance of Verano LLC and the comparative figures presented in the consolidated financial statements for dates and periods prior to the RTO are those of Verano LLC.
ASC 505-50, Equity-Based Payments to Non-Employees, applies to transactions where an entity grants equity instruments and cannot identify specifically some or all of the goods or services received in return. Because the Company issued shares with a value in excess of the assets received, the difference is recognized in RTO-related issuance cost through equity. The amount assigned to the transaction cost of $198 is the difference between the fair value of the consideration and the net identifiable assets of Majesta SubCo acquired by the Company.


1 Such amounts not in Thousands



10

VERANO HOLDINGS CORP.
Notes to Unaudited Interim Condensed Consolidated Financial Statements
($ in Thousands except shares and per share amounts)
3.INVENTORY
The Company’s inventory consists of the following as of September 30, 2022 and December 31, 2021:
September 30,
2022
December 31,
2021
(As Restated)
Raw Materials$6,702 $5,767 
Work in Process123,603 96,367 
Finished Goods37,837 38,569 
Total Inventory$168,142 $140,703 

4.PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment and related accumulated depreciation consists of the following as of September 30, 2022 and December 31, 2021:
September 30,
2022
December 31,
2021
Land$31,243 $29,399 
Buildings and Improvements184,556 126,020 
Furniture and Fixtures18,068 13,259 
Computer Equipment and Software23,035 14,078 
Leasehold Improvements207,262 182,514 
Tools and Equipment86,933 65,774 
Vehicles4,836 3,229 
Assets Under Construction (1)
53,813 64,107 
Total Property, Plant and Equipment609,746 498,380 
Less: Accumulated Depreciation(75,993)(46,148)
Property, Plant and Equipment, Net$533,753 $452,232 
(1)Assets under construction represent construction in progress related to facilities not yet completed or otherwise not placed in service.
For the three months ended September 30, 2022 and September 30, 2021, depreciation expense included in costs of goods sold totaled $8,504 and $5,770, respectively. For the three months ended September 30, 2022 and September 30, 2021, depreciation expense included in selling, general, and administrative expense totaled $2,782 and $1,932, respectively. For the nine months ended September 30, 2022 and September 30, 2021, depreciation expense included in costs of goods sold totaled $22,871 and $14,575, respectively. For the nine months ended September 30, 2022 and September 30, 2021, depreciation expense included in selling, general, and administrative expense totaled $8,502 and $5,066, respectively.
11


VERANO HOLDINGS CORP.
Notes to Unaudited Interim Condensed Consolidated Financial Statements
($ in Thousands except shares and per share amounts)
5.INTANGIBLE ASSETS AND GOODWILL
Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value as of the acquisition date. Amortization of definite life intangible assets is provided on a straight-line basis over their estimated useful lives. The estimated useful lives, residual values, and amortization methods for intangible assets are reviewed by the Company at each year end, and any changes in estimates are accounted for prospectively.
As of September 30, 2022, intangible assets consisted of the following:
LicensesTradenamesTechnologyTotal
Cost
Balance as of January 1, 2022$1,386,131 $54,166 $11,603 $1,451,900 
Purchases— — — — 
Additions from business combination21,545   21,545 
Adjustments to purchase price allocation    
Disposals    
Balance as of September 30, 2022$1,407,676 $54,166 $11,603 $1,473,445 
Accumulated Amortization
Balance as of January 1, 202266,703 4,158 1,126 71,987 
Amortization69,869 4,065 923 74,857 
Balance as of September 30, 2022$136,572 $8,223 $2,049 $146,844 
Net Book Value
Balance as of January 1, 20221,319,428 50,008 10,477 1,379,913 
Balance as of September 30, 2022$1,271,104 $45,943 $9,554 $1,326,601 
Amortization periods of assets with finite lives are based on management’s estimates as of the date of acquisition.
The following table outlines the estimated annual amortization expense related to intangible assets as of September 30, 2022:
Year Ending December 31:Estimated Amortization
2022 (Remaining)$25,125 
2023100,499 
2024100,499 
2025100,499 
202699,772 
Thereafter900,207 
$1,326,601 
12

VERANO HOLDINGS CORP.
Notes to Unaudited Interim Condensed Consolidated Financial Statements
($ in Thousands except shares and per share amounts)
5.INTANGIBLE ASSETS AND GOODWILL (Continued)
The changes in the carrying amount of goodwill, by reportable segment, for the nine months ended September 30, 2022 were as follows:
January 1, 2022ImpairmentAdjustments to purchase price allocationAcquisitionsSeptember 30, 2022
Cultivation$91,116 $ $1,050 $ $92,166 
Retail277,014  912 10,316 288,242 
Total$368,130 $ $1,962 $10,316 $380,408 
During the quarter ended March 31, 2022, the Company recorded measurement period adjustments in connection with the December 28, 2021 acquisition of Connecticut Pharmaceutical Solutions, Inc. The net impact led to an increase of $1,050 to goodwill. The Company obtained additional information about the facts and circumstances that existed at the time of the acquisition that resulted in changes in the provisional amounts recognized for inventory, income taxes and accrued payables.
During the quarter ended September 30, 2022, the Company recorded a purchase price adjustment for the December 20, 2021 acquisition of Caring Nature, LLC. The purchase price adjustment was an increase to consideration transferred and was reflected as an increase of $56 to goodwill.
During the quarter ended September 30, 2022, the Company recorded measurement period adjustments in connection with the March 11, 2022 acquisition of 420 Capital Management, LLC ("Greengate"). The net impact led to an increase of $856 to goodwill. The Company obtained additional information about the facts and circumstances that existed at the time of the acquisition that resulted in changes in the provisional amounts recognized for cash and accounts payable.

6.EARNINGS (LOSSES) PER SHARE
The Company presents basic earnings (losses) per share. Basic earnings (losses) per share is calculated by dividing the earnings (loss) attributable to shareholders by the weighted average number of Subordinate Voting Shares (with outstanding Proportionate Voting Shares accounted for on an as converted to Subordinate Voting Shares basis) outstanding during the periods presented.
13

VERANO HOLDINGS CORP.
Notes to Unaudited Interim Condensed Consolidated Financial Statements
($ in Thousands except shares and per share amounts)
6.EARNINGS (LOSSES) PER SHARE (Continued)
The computations of net earnings (loss) per share on a basic basis, including reconciliations of the numerators and denominators, for the three and nine months ended September 30, 2022 and September 30, 2021 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2022202120222021
Numerator
Net Loss attributable to Verano Holdings Corp.$(42,993)$(12,513)$(53,054)$(50,087)
Denominator
Basic
Pre-RTO weighted-average shares outstanding— — — 158,203,932 
Post-RTO weighted-average shares outstanding— 313,674,044 — 303,832,637 
Weighted-average shares outstanding – basic332,872,464 313,674,044 329,240,200 281,961,659 
Diluted
Pre-RTO weighted-average shares outstanding—